Weight loss drug's hidden toll: new study tracks muscle loss
NCT ID NCT07272837
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study uses advanced MRI scans to track changes in muscle and fat in the body and heart over 12 months in 50 adults starting semaglutide for type 2 diabetes or weight loss. Participants will undergo MRI scans, physical tests, blood samples, and questionnaires. The goal is to understand how semaglutide affects muscle health to ensure long-term well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mazankowski Alberta Heart Institute
RECRUITINGEdmonton, Alberta, T6G 0M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?